Table 2.

Effect of C. asiatica on physical fitness measured by 30-s chair stand test and 6-min walk test.

Items	Pre-dose baseline score		Post-dose score
			1 month	2 month	3 month	Delay
30-s chair stand test (times)					16.05 ± 2.72	16.10 ± 3.67
	Placebo	15.85 ± 2.87	15.65 ± 2.80	15.70 ± 2.99	F(0.0500, 3.57) = 0.3352,	F(0.0500, 1.19) = 0.1351,
					P = .7999	P = .7172
					20.35 ± 4.82a,∗∗	18.60 ± 5.96
	CA250	16.85 ± 4.21	18.40 ± 4.07	18.35 ± 4.85	F(0.0500, 3.57) = 5.2662,	F(0.0500, 1.19) = 2.2391,
					P = .0028	P = .1510
					20.35 ± 3.66b,∗∗	17.30 ± 4.03
	CA500	16.80 ± 4.36	17.75 ± 3.80	19.90 ± 4.10a,∗∗	F(0.0500, 3.57) = 23.3794,	F(0.0500, 1.19) = 1.3768,
					P < .0001	P = .2551
					21.00 ± 4.48b,∗∗∗	17.90 ± 5.93
	CA750	16.80 ± 3.09	17.45 ± 3.53	18.55 ± 3.17a,∗	F(0.0500, 3.57) = 13.9752,	F(0.0500, 1.19) = 0.9200,
					P < .0001	P = .3495
6 min walk test (meters)					518.35 ± 59.62	510.55 ± 78.06
	Placebo	515.60 ± 42.18	509.45 ± 55.78	504.95 ± 57.32	F(0.0500, 3.57) = 1.0645,	F(0.0500, 1.19) = 0.1759,
					P = .3714	P = .6796
					535.60 ± 52.40	519.25 ± 81.86
	CA250	517.60 ± 59.75	527.95 ± 42.34	524.25 ± 49.77	F(0.0500, 3.57) = 1.6551,	F(0.0500, 1.19) = 0.0155,
					P = .1869	P = .9022
					521.35 ± 66.20	512.00 ± 67.95
	CA500	509.50 ± 57.38	517.00 ± 64.62	523.10 ± 67.8	F(0.0500, 3.57) = 1.8655,	F(0.0500, 1.19) = 0.0355,
					P = .1457	P = .8526
					524.75 ± 80.68	520.55 ± 87.65
	CA750	511.75 ± 54.12	517.80 ± 75.67	529.05 ± 82.27	F(0.0500, 3.57) = 1.2784,	F(0.0500, 1.19) = 0.5046,
					P = .2905	P = .4861

Subjects were measured physical fitness measured by 30-s chair stand test and 6-min walk test. Data are presented as mean ± SD. P- and F-values were compared between pre-dose baseline score and post-dose 1, 2, 3 month and 1 month after cessation of treatment (n = 20/group).^{a, b} P-value <.01 and.001 compared with pre-dose baseline score, respectively.

*, **, ***P-value <.05,  .01 and  .001 compared with placebo treated group, respectively.